Myelin Basic Protein Administration in Multiple Sclerosis

Sixty-four subjects served in a doubleblind trial to test the efficacy of desensitization to human myelin basic protein (BP) as a therapy in multiple sclerosis. A difference appeared in the self-evaluation of the patients of the two groups, the experimentals appearing statistically better at periods late in the trial. Some patients were able to tell the BP from the placebo by a feeling of well-being, which the protein induced, others by improvement of bladder control or feeling of fatigue. No adverse reactions were encountered. The approach appears valid and should be pursued further with larger doses of BP or with the synthetic peptide fragments.